EnCare Biotech Overview

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

EnCare Biotech General Information

Description

Developer of novel therapeutic monoclonal antibody intended to treat EDA fragment of fibronectin. The company's novel therapeutic monoclonal antibody offers an innovative therapy for the prevention of chronic heart failure after myocardial infarction, enabling doctors to help patients prevent heart failure.

Contact Information

Website
www.encarebiotech.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Yalelaan 46
  • 3584 CM Utrecht
  • Netherlands
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • Yalelaan 46
  • 3584 CM Utrecht
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EnCare Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 10-Jan-2022 Completed Out of Business
4. Grant 02-Feb-2017 Completed Generating Revenue
3. Secondary Transaction - Private Completed Generating Revenue
2. Early Stage VC (Series A) 17-Nov-2014 $6.91M $6.91M Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2010 Completed Startup
To view EnCare Biotech’s complete valuation and funding history, request access »

EnCare Biotech Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • Pending

  • Expiring in next 12 mo

EnCare Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3788073-A2 Improved anti-fibronectin eda antibodies Inactive 03-May-2018
US-20210095011-A1 Improved anti-fibronectin eda antibodies Inactive 03-May-2018
AU-2015361294-A1 Immunoglobulin-like molecules directed against fibronectin-eda Inactive 12-Dec-2014
CA-2970427-A1 Immunoglobulin-like molecules directed against fibronectin-eda Inactive 12-Dec-2014
EP-3230313-A2 Immunoglobulin-like molecules directed against fibronectin-eda Inactive 12-Dec-2014 C07K16/18
To view EnCare Biotech’s complete patent history, request access »

Ready to get started?

Request a free trial

EnCare Biotech FAQs

  • Where is EnCare Biotech headquartered?

    EnCare Biotech is headquartered in Utrecht, Netherlands.

  • What industry is EnCare Biotech in?

    EnCare Biotech’s primary industry is Drug Discovery.

  • Is EnCare Biotech a private or public company?

    EnCare Biotech is a Private company.

  • What is EnCare Biotech’s current revenue?

    The current revenue for EnCare Biotech is .

  • How much funding has EnCare Biotech raised over time?

    EnCare Biotech has raised $6.91M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »